REGENXBIO/$RGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
353
ISIN
US75901B1070
Website
REGENXBIO Metrics
BasicAdvanced
$450M
-
-$3.10
1.11
-
Price and volume
Market cap
$450M
Beta
1.11
52-week high
$15.36
52-week low
$5.04
Average daily volume
1.2M
Financial strength
Current ratio
2.935
Quick ratio
2.821
Long term debt to equity
30.279
Total debt to equity
48.697
Interest coverage (TTM)
-8.17%
Management effectiveness
Return on assets (TTM)
-17.56%
Return on equity (TTM)
-47.44%
Valuation
Price to revenue (TTM)
2.914
Price to book
1.64
Price to tangible book (TTM)
1.64
Price to free cash flow (TTM)
-5.253
Growth
Revenue change (TTM)
80.70%
Earnings per share change (TTM)
-47.21%
3-year revenue growth (CAGR)
-30.84%
3-year earnings per share growth (CAGR)
10.62%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $450M as of May 30, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of May 30, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.